Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2017 Mar 30;15(10):1580–1588.e3. doi: 10.1016/j.cgh.2017.03.031

Figure 3.

Figure 3

Treatment failure (A), inflammatory bowel disease (IBD)–related surgery (B), IBD-related hospitalization (C), antibodies to infliximab (D), and serious infusion reaction (E) by infliximab trough concentration quartiles at start of therapeutic drug monitoring.